The ESR1-mutated Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“ESR1-mutated Metastatic Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the ESR1-mutated Metastatic Breast Cancer Market.
Some of the key takeaways from the ESR1-mutated Metastatic Breast Cancer Pipeline Report:
- Companies across the globe are diligently working toward developing novel ESR1-mutated Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years.
- ESR1-mutated Metastatic Breast Cancer companies working in the treatment market are Sun Pharma, Eisai Co Ltd, Olema Pharmaceuticals, Sermonix Pharmaceuticals, AstraZeneca, Radius Pharmaceuticals, Berlin-Chemie (Menarini Group), Pfizer, G1 Therapeutics, Zenopharm, Arvinas, H3 Biomedicine, Eisai, Roche, Zentalis Pharmaceuticals, and others, are developing therapies for the ESR1-mutated Metastatic Breast Cancer treatment
- Emerging ESR1-mutated Metastatic Breast Cancer therapies in the different phases of clinical trials are- SCO-120, H3B-6545, OP1250, Lasofoxifene, Camizestrant (AZD9833), Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), ZB716, ARV-471, H3B-6545, Giredestrant (RG6171, GDC-9545), ZN-c5, and others are expected to have a significant impact on the ESR1-mutated Metastatic Breast Cancer market in the coming years.
- On August 17, 2022, “Sanofi halted the worldwide clinical development initiative for amcenestrant, an experimental oral selective estrogen receptor degrader (SERD).”
- In August 2022, “Zentalis revealed the cessation of clinical development for ZN-c5, their oral SERD, and ZN-e4, an EGFR inhibitor. This decision was made after the completion of ongoing clinical trials in both programs, which are now closed for further participant enrollment.”
- In August 2022, “The FDA has given priority review status to the New Drug Application (NDA) for elacestrant intended for treating patients diagnosed with estrogen receptor (ER)-positive/HER2-negative advanced or metastatic breast cancer. The regulatory agency is anticipated to make a decision on the application by February 17, 2023, in accordance with the Prescription Drug User Fee Act.”
- In August 2022, “The FDA has awarded OP-1250 a fast-track designation for addressing patients diagnosed with ER-positive, HER2-negative metastatic breast cancer.”
- In April 2022, Roche announced the first-quarter result and stated that giredestrant missed the mark in the Phase II acelERA trial in advanced breast cancer, the emerging oral selective estrogen receptor degrader (SERD) class.
- On October 21, 2022, “Sermonix Pharmaceuticals Inc., a private biopharmaceutical firm dedicated to developing innovative treatments for ESR1-mutated metastatic breast and gynecological cancers, shared further results from its Phase II Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) study at the 4th Annual Congress of the International Society of Liquid Biopsy (ISLB) in Miami.”
ESR1-mutated Metastatic Breast Cancer Overview
In essence, metastatic breast cancer is a kind of Stage IV breast cancer in which the cancer starts in the breast tissue and subsequently spreads to other places of the body. The majority of human breast cancers begin as estrogen-dependent tumors that express the estrogen receptor (ER), and the steroid hormone estradiol plays a critical role in the evolution of breast cancer.
Get a Free Sample PDF Report to know more about ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-pipeline-insight
Emerging ESR1-mutated Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:
- SCO-120: Sun Pharma Advanced Research Company Ltd
- H3B-6545: Eisai Co Ltd
- OP1250: Olema Pharmaceuticals
- Lasofoxifene: Sermonix Pharmaceuticals
- Camizestrant (AZD9833): AstraZeneca
- Elacestrant (RAD1901): Radius Pharmaceuticals/Berlin-Chemie (Menarini Group)
- Ibrance (Palbociclib): Pfizer
- Rintodestrant (G1T48): G1 Therapeutics, Inc.
- ZB716: Zenopharm
- ARV-471: Arvinas
- H3B-6545: H3 Biomedicine/Eisai
- Giredestrant (RG6171, GDC-9545): Roche
- ZN-c5: Zentalis Pharmaceuticals
ESR1-mutated Metastatic Breast Cancer Route of Administration
ESR1-mutated Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
ESR1-mutated Metastatic Breast Cancer Molecule Type
ESR1-mutated Metastatic Breast Cancer Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutics Assessment
- ESR1-mutated Metastatic Breast Cancer Assessment by Product Type
- ESR1-mutated Metastatic Breast Cancer By Stage and Product Type
- ESR1-mutated Metastatic Breast Cancer Assessment by Route of Administration
- ESR1-mutated Metastatic Breast Cancer By Stage and Route of Administration
- ESR1-mutated Metastatic Breast Cancer Assessment by Molecule Type
- ESR1-mutated Metastatic Breast Cancer by Stage and Molecule Type
DelveInsight’s ESR1-mutated Metastatic Breast Cancer Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further ESR1-mutated Metastatic Breast Cancer product details are provided in the report. Download the ESR1-mutated Metastatic Breast Cancer pipeline report to learn more about the emerging ESR1-mutated Metastatic Breast Cancer therapies
Some of the key companies in the ESR1-mutated Metastatic Breast Cancer Therapeutics Market include:
Key companies developing therapies for ESR1-mutated Metastatic Breast Cancer are – Eisai, Roche, AstraZeneca, Sun Pharma, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine, Radius Pharmaceuticals, Berlin-Chemie, Pfizer, G1 Therapeutics, Inc., Zentalis Pharmaceuticals, Olema Pharmaceuticals, and others.
ESR1-mutated Metastatic Breast Cancer Pipeline Analysis:
The ESR1-mutated Metastatic Breast Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of ESR1-mutated Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESR1-mutated Metastatic Breast Cancer Treatment.
- ESR1-mutated Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- ESR1-mutated Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESR1-mutated Metastatic Breast Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about ESR1-mutated Metastatic Breast Cancer drugs and therapies
ESR1-mutated Metastatic Breast Cancer Pipeline Market Drivers
- Rise in global prevalence of ESR1 gene in Metastatic Cancer, increasing research and development activities, technological advancements are some of the important factors that are fueling the ESR1-mutated Metastatic Breast Cancer Market.
ESR1-mutated Metastatic Breast Cancer Pipeline Market Barriers
- However, poor Understanding of the disease and its prognosis, lack of Efficient Diagnostic Tools and other factors are creating obstacles in the ESR1-mutated Metastatic Breast Cancer Market growth.
Scope of ESR1-mutated Metastatic Breast Cancer Pipeline Drug Insight
- Coverage: Global
- Key ESR1-mutated Metastatic Breast Cancer Companies: Sun Pharma, Eisai Co Ltd, Olema Pharmaceuticals, Sermonix Pharmaceuticals, AstraZeneca, Radius Pharmaceuticals, Berlin-Chemie (Menarini Group), Pfizer, G1 Therapeutics, Zenopharm, Arvinas, H3 Biomedicine, Eisai, Roche, Zentalis Pharmaceuticals, and others
- Key ESR1-mutated Metastatic Breast Cancer Therapies: SCO-120, H3B-6545, OP1250, Lasofoxifene, Camizestrant (AZD9833), Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), ZB716, ARV-471, H3B-6545, Giredestrant (RG6171, GDC-9545), ZN-c5, and others
- ESR1-mutated Metastatic Breast Cancer Therapeutic Assessment: ESR1-mutated Metastatic Breast Cancer current marketed and ESR1-mutated Metastatic Breast Cancer emerging therapies
- ESR1-mutated Metastatic Breast Cancer Market Dynamics: ESR1-mutated Metastatic Breast Cancer market drivers and ESR1-mutated Metastatic Breast Cancer market barriers
Request for Sample PDF Report for ESR1-mutated Metastatic Breast Cancer Pipeline Assessment and clinical trials
Table of Contents
1. ESR1-mutated Metastatic Breast Cancer Report Introduction
2. ESR1-mutated Metastatic Breast Cancer Executive Summary
3. ESR1-mutated Metastatic Breast Cancer Overview
4. ESR1-mutated Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutics
6. ESR1-mutated Metastatic Breast Cancer Late Stage Products (Phase II/III)
7. ESR1-mutated Metastatic Breast Cancer Mid Stage Products (Phase II)
8. ESR1-mutated Metastatic Breast Cancer Early Stage Products (Phase I)
9. ESR1-mutated Metastatic Breast Cancer Preclinical Stage Products
10. ESR1-mutated Metastatic Breast Cancer Therapeutics Assessment
11. ESR1-mutated Metastatic Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. ESR1-mutated Metastatic Breast Cancer Key Companies
14. ESR1-mutated Metastatic Breast Cancer Key Products
15. ESR1-mutated Metastatic Breast Cancer Unmet Needs
16 . ESR1-mutated Metastatic Breast Cancer Market Drivers and Barriers
17. ESR1-mutated Metastatic Breast Cancer Future Perspectives and Conclusion
18. ESR1-mutated Metastatic Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services